24/7 Market News Snapshot 06 May, 2025 – Pasithea Therapeutics Corp. Common Stock (NASDAQ:KTTA)

May 6, 2025

DENVER, Colo., 06 May, 2025 (www.247marketnews.com) – (NASDAQ:KTTA) are discussed in this article.
Pasithea Therapeutics Corp (KTTA) is experiencing a remarkable surge in its stock market performance, opening today at $2.21 and rising impressively to $2.361, which represents an increase of 66.27% from its previous closing price of $1.42. This significant upward movement can be attributed to strong investor interest, reflected in a trading volume of 185.36 million shares, indicating a heightened bullish sentiment among market participants eager to engage with KTTA’s promising prospects.

In addition to the stock market activity, Pasithea recently announced a successful public offering, a strategic milestone aimed at bolstering its operational capabilities. The company priced the offering of 3,571,428 shares of common stock, which includes Series C and Series D warrants, at an appealing combined price of $1.40 per share. The Series C warrants are exercisable immediately upon issuance for five years, while Series D warrants will also be effective upon issuance but will expire after 18 months. The offering is expected to close on or about May 7, 2025, pending customary closing conditions.

This public offering is projected to yield approximately $5 million in gross proceeds, providing essential funding to support various strategic initiatives. Pasithea plans to allocate the net proceeds to vital research and development efforts, clinical trials, and the enhancement of innovative therapies. The company is also exploring potential partnerships and acquisitions that align with its growth objectives, further expanding its capabilities within the biotechnology sector.

With these significant developments, Pasithea Therapeutics is well-positioned to advance its clinical programs and reinforce its commitment to delivering innovative treatments for patients suffering from complex conditions such as neurofibromatosis type 1 (NF1) and various cancer indications. Through this funding, Pasithea is dedicated to pioneering solutions that offer hope to those in need.

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.